14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SPXV vs ABFL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, ProShares S&P 500 Ex-Health Care ETF (SPXV) is the stronger overall head-to-head candidate over Abacus FCF Leaders ETF (ABFL) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). SPXV carries a Unified Composite Score of 39.6/100 (SELL) at $74.11 (N/M Forward P/E, N/A operating margin), whereas ABFL carries 36.4/100 (SELL) at $69.81 (N/M Forward P/E, N/A operating margin).
Defensive Composite Rating Caution: Although SPXV compares more favorably head-to-head, both SPXV (39.6/100 SELL) and ABFL (36.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: SPXV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.7); meanwhile ABFL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPXV vs ABFL. Trailing 12-month operating profitability (SPXV N/A vs ABFL N/A) and valuation multiples (SPXV N/M vs ABFL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SPXV vs ABFL Key Questions & Quantitative Answers
As of Nov 20, 2026, ProShares S&P 500 Ex-Health Care ETF (SPXV) is the stronger overall head-to-head candidate over Abacus FCF Leaders ETF (ABFL) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). SPXV carries a Unified Composite Score of 39.6/100 (SELL) at $74.11 (N/M Forward P/E, N/A operating margin), whereas ABFL carries 36.4/100 (SELL) at $69.81 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although SPXV compares more favorably head-to-head, both SPXV (39.6/100 SELL) and ABFL (36.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SPXV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.7); meanwhile ABFL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SPXV and ABFL split Growth & Scale metrics: SPXV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABFL at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, SPXV generates N/A in USD-normalized revenue versus N/A for ABFL. In operating R&D and SG&A reinvestment, SPXV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABFL.
SPXV and ABFL trade at balanced relative valuation multiples. SPXV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABFL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPXV (N/A ROE) versus ABFL (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, SPXV carries 221.1% implied volatility (92nd %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 25% Vol realized risk). By comparison, ABFL carries 48.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.06β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.